The FDA announced that it has approved Astellas Pharma’s VESIcare LS oral suspension for the treatment of neurogenic detrusor overactivity, or NDO, in children aged 2 years and older.
We’re sorry, but an unexpected error has occurred.
Please refresh your browser and try again. If this error persists, please contact ITSupport@wyanokegroup.com for assistance.
Would you like to receive email reminders to complete your saved activities from Healio CME?
Activity saved! You'll receive reminders to complete your saved activities from Healio CME.
